Sanofi: Barclays raises target price

(CercleFinance.com) - Barclays confirms its 'overweight' recommendation on Sanofi shares, with a target price raised from E120 to E125, believing that 2025 could be the year that sees the French healthcare giant's shares break through the E105 threshold.


Although Dupixent missed expectations in the quarter, everything else at Sanofi is progressing well (and we believe that the launch in COPD this year should benefit Dupixent), the broker summarises.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.